INM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InMed Pharmaceuticals Inc (INM) is not a good buy for a beginner investor with a long-term strategy at this time. The financial performance is weak, technical indicators are mixed with bearish trends, and there are no significant positive catalysts or trading signals to support a buy decision.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.848, with key resistance at 0.933 and support at 0.764. Overall, the technical outlook is mixed but leans bearish.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock is down -2.85% in pre-market trading. Financial performance has significantly deteriorated, with revenue, net income, EPS, and gross margin all showing substantial YoY declines. No recent news or events to drive positive sentiment.
In the latest quarter (2026/Q2), revenue dropped -26.22% YoY to $820,188. Net income declined -21.23% YoY to -$2,028,223. EPS fell -85.99% YoY to -0.51, and gross margin dropped -49.65% YoY to 15.97%. The financials indicate significant weakness and no signs of growth.
No analyst rating or price target data available. Wall Street sentiment is neutral with no clear pros or cons identified.
